Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
News
ASX Large Caps: Shares 1pc higher as Neuren, Block surge; SBF found guilty of all charges
Health & Biotech
ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer’s data
News
ASX Large Caps: ASX falls 1.28pc to hit 100-day low, RBA keeps rates on hold for now
Health & Biotech
ScoPo’s Powerplays: Who remembers that time they died? Oh, and Ramsay Healthcare cops credit downgrade
Health & Biotech
2023 ASX biotech darling Neuren among sector stocks with upcoming catalysts
Health & Biotech
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
News
ASX Small Caps Lunch Wrap: Who else is up to something totally pointless today?
News
Selfwealth names top ASX gainers for August; UBS says sell them in September
Health & Biotech
ScoPo’s Powerplays: Should have stayed in bed as ASX stocks fall but Neuren makes S&P ASX 200
News
ASX Rebalance: Biotech Neuren enters S&P ASX 200, Harvey Norman booted and Liontown makes the top 100
News
ASX Earnings Wrap: AI stock Appen plunges, Helloworld says local travel agents making a comeback
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Health & Biotech
Move over Neuren – Bioshares reckons these ASX health stocks could pop with upcoming key catalysts
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Experts
MoneyTalks: Why Peak Asset Management is betting on these biotech and lithium plays
Health & Biotech
ScoPo’s Powerplays: ASX health stock fall but hold onto your hat for reporting season
Health & Biotech